CN117024525A - 一种白细胞提取物的制备以及在化妆品和药品中的应用 - Google Patents
一种白细胞提取物的制备以及在化妆品和药品中的应用 Download PDFInfo
- Publication number
- CN117024525A CN117024525A CN202311017323.7A CN202311017323A CN117024525A CN 117024525 A CN117024525 A CN 117024525A CN 202311017323 A CN202311017323 A CN 202311017323A CN 117024525 A CN117024525 A CN 117024525A
- Authority
- CN
- China
- Prior art keywords
- antibacterial
- extract
- leukocyte extract
- application
- leukocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 43
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 35
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 21
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- 230000035755 proliferation Effects 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 210000000822 natural killer cell Anatomy 0.000 claims description 17
- 241000191967 Staphylococcus aureus Species 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract description 8
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 210000004962 mammalian cell Anatomy 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- 229920001184 polypeptide Polymers 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- -1 PDGF Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100037383 Gasdermin-B Human genes 0.000 description 2
- 101001026281 Homo sapiens Gasdermin-B Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 241000235342 Saccharomycetes Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- VBCKYDVWOPZOBA-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxymethyl)oxolane Chemical class C1CCOC1COCC1CCCO1 VBCKYDVWOPZOBA-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- RKZDVJXXUQXJCF-UHFFFAOYSA-N CC1COC(=O)O1.CCCCCC(O)(O)O Chemical compound CC1COC(=O)O1.CCCCCC(O)(O)O RKZDVJXXUQXJCF-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种白细胞提取物的制备以及在化妆品和药品中的应用。本发明提供了一种白细胞提取物，分离自哺乳动物细胞，所述提取物具有较好的抗菌及抗氧化特性。将所述的白细胞提取物与抗菌肽一起使用后，能够有效的抑制病原菌的增殖，具有较好的治疗效果。可以将所述的白细胞提取物与抗菌肽制备成为相应的药物或者化妆品。
Description
技术领域
本申请涉及生物领域，具体的涉及一种白细胞提取物的制备以及在化妆品和药品中的应用。
背景技术
白细胞提取物(LEUKOCYTE EXTRACT)是从白细胞中提取的一种细胞分泌的复合物。白细胞提取物中含有大量细胞特异性蛋白(PDGF、VEGF、HGF、PDGF、bFGF、TGF-β、EGF等几百种修复因子)、脂质、核酸(DNA、RNA)等，可直接作用于粘膜层，其透皮吸收率高，对成纤维细胞、上皮细胞、内皮细胞等都具有促进增殖分裂、促进血管新生及粘膜修复和细胞再生等作用。这些成分可以有效激活衰老细胞、促进细胞新生、修复炎症损伤、提高皮肤免疫、减少色素沉着等等，帮助身体中的细胞恢复正常的功能和活力。因此，白细胞提取物常被作为抗氧化剂的药物或者加入到护肤品中。
由于夏季紫外线强烈，紫外线辐射导致的炎症因子会刺激黑色素细胞，黑色素细胞受到刺激便会产生黑色素。许多人皮肤会生长出斑点、甚至出现晒红、晒伤。在紫外线辐射下，皮肤细胞内会产生一种自由基。夏季日晒后的肌肤护理，抗氧化是重中之重，选择白细胞提取物护肤品，帮助我们快速走出日晒损伤，恢复肌肤透亮。体内自由基过多正是人老化、体力衰退、皮肤失去光泽和弹性的主要原因。当自由基的生成量，超过皮肤清除自由基极限时，皮肤发生自由基的积聚，就会对皮肤产生严重的影响，比如胶原蛋白和弹力蛋白的受损，你会感受到自己的皮肤变得干燥，失去光泽和弹性。而白细胞提取物作为抗氧化剂，它具有再生、增加细胞活力，抑制酪氨酸酶的活性的效果。酪氨酸酶是一种氧化酶，具有调控黑色素生成的作用，能够有效抑制黑色素异常合成，起到淡化色素、色斑的作用。此外，它还能刺激细胞外一些大分子，如透明质酸和糖蛋白等的合成和分泌，有助于滋润皮肤，促进皮肤新陈代谢，可以将日晒后过量的色素沉积代谢出去，加快皮肤愈合。
防腐体系是化妆品中必不可少的重要组成部分。由于化妆品本身含有大量的营养成分，如油脂和功效提取物等，这些成分极有利于微生物的生长和繁殖，产品一旦被微生物污染则很容易腐败变质，所以为了使化妆品在其保质期内及消费者使用期间不被微生物污染，化妆品中必然要添加一定量的防腐剂。随着崇尚自然的消费理念逐步得到人们的认可，天然防腐剂的研究与开发也成为防腐剂领域的研究热点。国内外研究者纷纷从不同植物中得到一些抑菌物质，并试图将其开发成防腐剂。嗜热链球菌发酵产物主要是由嗜热链球菌发酵并提纯得到的多肽结构化合物，其分子中的羧基和氨基形成酰胺键连接成多聚体，是具有20～30个赖氨酸单体组成的化合物，和盐酸进一步反应后得到一种分子量介于3500～4500之间的高纯度水溶性化合物。其可与微生物表面带负电的位点结合，并破坏微生物的细胞膜结构，从而引起细胞膜间物质传递的中断，导致微生物细胞死亡。曲霉发酵产物主要由曲霉发酵并提纯得到。其作用机理是：霉菌和酵母菌的细胞壁结构特殊，存在一种甾醇特殊结构的化合物，AF与甾醇发生化学反应，使其结构发生改变，迫使细胞内的物质发生渗漏，导致霉菌和酵母菌死亡，故其针对霉菌具有较好的抑菌作用。因此，微生物源天然防腐剂取代合成类防腐剂用于化妆品配方抑菌。
但是，目前有效的抑菌肽种类还不够多，特别是具有广谱特性的抑菌肽的开发还有待进一步的提高。
发明内容
本发明一方面，从牛血液中分离制备得到特异性的牛白细胞-NK细胞及其提取物，所述提取物本身具有较好的抑菌特性。
研究表明，细菌感染过程中，宿主NK细胞(natural killer cell，自然杀伤细胞)体内含有颗粒酶A(granzyme A，GZMA)，能够介导宿主上皮细胞中GSDMB的活化。而活化的N端GSDMB能够靶向到革兰氏阴性菌内膜上的心磷脂(CL)，从而杀伤并清除细菌。因此，本发明的牛白细胞-NK细胞提取物能够抑制小鼠模型中的细菌增殖。
此外，本发明还从牛血液中分离获得了天然的具有抑菌特性的活性肽，所述活性肽具有较好的抑制病原菌的特性，同时还具有抗氧化特性。
进一步的，所述的活性肽序列为SEQ ID No：1所示，所述的病原菌是金黄色葡萄球菌ATCC25923、大肠杆菌ATCC35218、副溶血弧菌ATCC 33845。
进一步的，本发明提供一种抑菌的组合物，其中含有NK细胞提取物和序列为SEQID No：1所示的活性肽。
进一步的，本发明提供一种抑菌的组合物，其中含有SEQ ID No：1所示的活性肽。
进一步的，所述组合物针对的离体的细菌。
进一步的，所述组合物针对的是动物。
本发明的组合物还可以与常用赋形剂混合而使用，所述的常用赋形剂即药物上可接受的适合于非肠道、肠道(例如口服或吸入)或局部施用的有机或无机载体物质，它们不与活性组合物发生有害反应。合适的药物上可接受的载体包括但不限于：水；盐溶液；醇类；阿拉伯树胶；植物油；苄醇类；聚乙二醇类；明胶；碳水化合物，诸如乳糖、直链淀粉或淀粉；硬脂酸镁；滑石；硅酸；粘性石蜡；芳香油；脂肪酸酯类；羟甲基纤维素；聚乙烯吡咯烷酮等。可以对药物制剂灭菌且如果需要，将其与助剂混合，例如润滑剂、防腐剂、稳定剂、湿润剂、乳化剂、影响渗透压的盐、缓冲剂、着色剂、调味剂和/或芳香物质等，它们不与活性组合物发生有害反应。如果需要，还可以将它们与其它活性剂合并，例如维生素。在具体的实施方案中，所述的液体载体还可以含有增稠剂，例如蜂蜡、硬石蜡或鲸蜡醇。作为可选的添加剂注意到的还有苄醇类、聚乙二醇类、粘性石蜡、芳香油和脂肪酸酯类。
适于本发明的赋形剂是药学上可接受的并且与聚原酸酯相容的物质。它们在室温下为液体，并且容易与聚原酸酯溶混。合适的赋形剂包括：具有200-4000的分子量的聚(乙二醇)醚衍生物，如聚(乙二醇)单-或二-烷基醚、优选聚(乙二醇)单甲基醚550或聚(乙二醇)二甲基醚250；具有400-4000的分子量的聚(乙二醇)共聚物，如聚(乙二醇-共-聚丙二醇)；C2-19脂肪族羧酸或这样的酸的混合物的丙二醇单-或二-酯，如丙二醇二辛酸酯或二癸酸酯；C2-19脂肪族羧酸或这样的酸的混合物的单-、二-或三-甘油酯，如辛酸甘油酯、癸酸甘油酯、辛酸甘油酯/癸酸甘油酯、辛酸甘油酯/癸酸甘油酯/月桂酸甘油酯、聚氧乙烯(2)四氢糠醚和类似的乙氧基化的四氢糠醇和它们的C1-4烷基醚和C2-19脂肪族羧酸酯；以及生物相容的油，如葵花油、芝麻油以及其它非氢化或部分氢化的植物油。这些物质中的大多数是商业上可获得的，
本发明的药物组合物优选施用于哺乳动物，如狗、猫、马、猪、大鼠，特别是人。
优选本发明的药物组合物以胶囊、片剂、口服液、粉剂等口服，或者作为用于肌内或静脉内给药的肠胃外组合物液体。
在一个优选的实施方案中，本发明提供一种适于口服的形式，特别是口服单元剂型的组合物，如其剂型为片剂、胶囊、饮用溶液或用于重使用前配制的干粉；或者由本领域中已知的标准技术如通过在沉积时喷雾包衣而制备的sohxlet形式。
特别适宜口服的单元剂型包括胶囊形式，如软或硬明胶胶囊形式，它是优选的口服剂型。患者的药物剂量和给药次数依赖于多种因素、患者的年龄、患者病症的严重程度、过去的服药史而变，并由内科医师合理考虑来决定。
当本发明的组合物制成软或硬胶囊的形式时，该组合物可以装入包含任何常规增塑剂的明胶胶囊壳内。由于在明胶囊壳中可以包含增塑剂，可以不受限制地使用一种或多种选自以下的增塑剂：甘油、山梨醇、己三醇碳酸异丙烯酯、己二醇、山梨聚糖、四氢呋喃基醇醚、二乙二醇一乙基醚、1，3-三甲基-2-咪唑啉酮、二甲基异山梨醇等。
但是，应该理解本发明中可以使用的增塑剂不限于上述这些。本发明的胶囊制剂可以在常规机器中，通过胶囊化所得的本发明乳液的预浓缩物，如含有或不含有上述药学上可接受的添加剂的微乳液预浓缩物而制备。
进一步的，本发明的组合物还用于抑菌的化妆品中的用途。所述化妆品一方面能够抑制本身的细菌生长，另外一方面，也能够抑制皮肤表面细菌的生长，提高皮肤的抗氧化特性。
有益效果
本发明提供了一种白细胞提取物，分离自哺乳动物细胞，所述提取物具有较好的抗菌特性。将所述的白细胞提取物与抗菌肽一起使用后，能够有效的抑制病原菌的增殖，具有较好的治疗效果。可以将所述的白细胞提取物与抗菌肽制备成为相应的药物或者化妆品。
附图说明
图1抗菌肽的抗氧化特性结果图
具体实施方式
本领域技术人员可以借鉴本文内容，适当改进工艺参数实现。特别需要指出的是，所有类似的替换和改动对本领域技术人员来说是显而易见的，它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述，相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合，来实现和应用本发明技术。以下实施案例中的方法、设备、材料，如果未进行特别说明，均为本领域常规方法、设备和材料，均可由市场购得。
实施例1白细胞提取物的制备
将牛外周血50ml肝素抗凝，用PBS等体积稀释后，用淋巴细胞分离液以密度梯度离心法分离得到单个核细胞PBMNC，PBS洗涤2次。将上述PBMNC用溶红素处理，然后用MACSbuffer洗涤1次，血细胞计数板计数。每107个细胞重悬于40μl MACS buffer，加入10μlNK cell biotin antibody cocktail，4℃孵育15分钟，然后依次加入30μlMACS buffer、20μlanti-biotin microbeads，4℃20r/min摇床孵育20分钟，再次用MACS buffer洗涤标记好的细胞1次，重悬于500μlMACSbuffer中。选用MS分离柱，安放于miniMACS分离器磁场中，使用前润湿分离柱，将分离柱放置于合适的细胞收集管上。将细胞悬液上柱，用4×500μlMACSbuffer洗柱，收集细胞。纯化前后计数单个核细胞，并以CD3、CD56荧光标记抗体分析NK细胞数，结果显示，NK细胞CD3-CD56+含量由分选前的不到12％提高到(95.3±0.7)％，获得了较为纯净的NK细胞。将纯化的NK细胞加入含有10％人AB血清、2mmol/L左旋谷氨酰胺、青、链霉素(各100U/ml)及细胞因子IL2(250U/ml)、IL15(15ng/ml)、IL12(5ng/ml)的NKMACS培养基内，调至细胞终浓度1×105/ml，然后接种于24孔板，每孔终体积为1ml，置37℃、5％CO2、饱和温度培养箱中培养，每3天半量换液并全量补充上述细胞因子。于培养第15天通过台盼蓝染色法计数并检测细胞活性。免疫表型分析将取自不同来源的细胞用荧光抗体CD3FITC、CD56PE标记，流式细胞仪检测发现，NK细胞纯度CD3-CD56+NK细胞纯度大于95％与开始培养时0天NK细胞纯度无显著差异(P<0.05)。细胞的扩增倍数为73倍。
将培养的NK细胞通过5000r/min离心10min，获得沉淀NK细胞，取200mg NK细胞用PBS缓冲液溶解，液氮冻融3次后，用超声破碎仪以10秒/次破碎，镜检破碎完毕后，4℃10000r/min离心30分钟，取上清，冷冻冻干即得到牛白细胞提取物。
实施例2抗菌肽的筛选分离
取牛血液2mL，加入抗凝剂，充分混匀，过滤后，用质量分数为0.83％的NH4Cl裂解红细胞，4℃下2500r/min离心10min，以沉淀白细胞。重复上述操作2次，并染色镜检，以保证沉淀中不含红细胞。将上述白细胞用高速组织捣碎机匀浆，以释放白细胞颗粒，经离心4℃，4000r/min15min收集细胞颗粒，悬浮于体积分数为10％的醋酸中，然后于4℃下搅拌过夜，次日于4℃15000r/min离心取上清，在旋转蒸发仪器蒸发除酸，冻干，然后用体积分数为0.01％的醋酸溶解，即为抗菌肽粗提物。将粗提物采用离子交换柱和反向高效液相色谱分离有活性的阳离子峰，采用琼脂糖弥散法测定离子交换柱和反向高效液相色谱分离的肽的抗微生物活性，所述微生物为大肠杆菌、金黄色葡萄球菌、副溶血弧菌。结果显示S3F8号多肽具有最好的抗菌活性，将该组分通过质谱鉴定，获得氨基酸序列如SEQ ID NO：1所示。
实施例3S3F8多肽的抗菌特性鉴定
培养基的制备：牛肉膏蛋白胨琼脂：牛肉膏3g，蛋白胨10g，NaC15g，琼脂20g，水1000mL，pH7.2，该培养基用于金黄色葡萄球菌ATCC25923和大肠杆菌ATCC35218的培养。
2216E琼脂：蛋白胨5g、酵母膏1g、柠檬酸铁0.1g、琼脂15g和过滤陈海水1000mL，调pH值为7.6，该培养基用于副溶血弧菌ATCC 33845的培养。液体培养基为相应的不加琼脂的培养基。
供试菌种的活化及菌悬液的制备：预先将3种供试菌种接入相对应的斜面培养基上进行活化，细菌置37℃恒温培养箱中培养24h，副溶血弧菌置28度恒温培养箱中培养48h，然后分别挑取一环已活化好的菌种放入9mL无菌生理盐水中，振荡摇匀，制成一系列菌悬液，浓度约为107cfu/mL，备用。
比浊法测定多肽抑菌活性：
取多肽于带塞的试管中，分别加入液体培养基，配制成含多肽终浓度分别为100μg/mL和200μg/mL的培养基各5.0mL，再分别加入50μL供试菌悬液，金黄色葡萄球菌和大肠杆菌置于37℃振荡培养24h；副溶血弧菌置于28℃振荡培养48h，用紫外分光光度计测量OD560值，并计算抑菌率。抑菌率(％)＝(对照组0D值-试验组OD值)/对照组OD值×lO0％。以100μg/mL的brevilaterin肽作为阳性对照，结果如表1所示。
表1 S3F8多肽的抑菌率
从表1的抑菌率显示本发明的多肽对细菌的抑制率随着浓度的增加而增加，对大肠杆菌的作用最强。在多肽浓度为200μg/mL时，对大肠杆菌和金黄色葡萄球菌抑制作用最强，对副溶血弧菌的抑制效果也较好，比阳性对照的抑制效果要好。
实施例4多肽的抗氧化性能实验
将多肽样品浓度调节为0.2mg/mL，以同浓度的Vc作为阳性对照。清除超氧阴离子自由基的测定：在比色管中分别加入0.2mL、0.4mL、0.6mL、0.8mL、1.OmL样品，加蒸馏水至lmL。加入Tris-HC1溶液(pH8.2)5.0mL和50mmol/L邻苯三酚溶液lmL，迅速摇匀，以蒸馏水为空白对照。每30s在波长325nm处测定吸光度值。按下式计算清除率。清除率＝(F0-Fs)×100％。式中：F0为邻苯三酚的自氧化速率；Fs为加样品的反应溶液吸光度值变化率。结果如图1所示。
本发明的多肽样品对超氧阴离子自由基的清除率测定结果见图1，由图1可知，多肽样品均具有较好的超氧阴离子自由基清除能力，且优于阳性对照组。同时清除率随其加入量的增大而增加。在浓度为0.5mg/mL时，清除率达到最大值(98.1±1.9)％。
实施例5白细胞提取物和抗菌肽的动物实验
将50只小鼠随机分成5组，每组1O只。实验组(1～3)及感染对照组(4)小鼠以腹腔注射金黄色葡萄球菌ATCC25923 100μL/只(5×107CFU/mL)；不感染对照组(5)小鼠仅肌肉注射0.1％乙酸。实验组(1)在注射金黄色葡萄球菌后，右腿肌肉注射实施例1制备的白细胞提取物浓度为1mg/mL的提取物100μL/只；实验组(2)在注射金黄色葡萄球菌后，右腿肌肉注射实施例2制备的多肽浓度为1mg/mL的提取物100μL/只；实验组(3)在注射金黄色葡萄球菌后，右腿肌肉注射实施例2制备的多肽浓度为1mg/mL的提取物100μL/只，左腿肌肉注射实施例1制备的白细胞提取物浓度为1mg/mL的提取物100μL/只；
各组小鼠分别置于不同的饲养箱中，自由饮水和采食饲料，每天观察2次临床表现，测量1次体重，记录临床症状和死亡情况。如小鼠死亡，则取其大脑组织进行涂片，并断尾取血制成血液涂片，革兰氏染色镜检，确定死因是否为菌感染。统计7d内各组小鼠的死亡情况，计算相对保护率(RPS)。结果如表2所示。
表2白细胞提取物和抗菌肽对小鼠感染的保护效果
| 组别 | 保护率(％) |
| 实验组1 | 70 |
| 实验组2 | 90 |
| 实验组3 | 100 |
小鼠在感染金黄色葡萄球菌时，模型组死亡率达到90％。而通过给小鼠注射血白细胞提取物和多肽，对小鼠抗金黄色葡萄球菌都有一定的效果。从小鼠的死亡情况看，各实验组小鼠死亡数无显著差异(P>0.05)，都获得了明显的保护，而实验组与感染对照组则差异显著(P<0.01)，感染对照组出现严重死亡，死亡率达到90％。实验结果表明，实验组1小鼠分别获得了70％的相对保护率；实验组2小鼠分别获得了90％的相对保护率；实验组3小鼠获得了100％的相对保护率。
实施例6白细胞提取物和本发明的多肽安全性鉴定
安全性检测：取小鼠1O只，以白细胞提取物和本发明的多肽(浓度均为1×103μg/mL)腹腔注射5只小鼠(200μL/只)，另设对照组以生理盐水腹腔注射5只小鼠(200μL/只)，观察7d内小鼠的健康状况及存活情况。
结果显示，小鼠未产生任何不良反应，其摄食、运动均正常，说明高浓度的白细胞提取物和多肽的安全性均达到了机体注射的要求，具有较好的安全性。
在本说明书的描述中，参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中，对上述术语的示意性表述不一定指的是相同的实施例或示例。而且，描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。尽管已经示出和描述了本发明的实施例，本领域的普通技术人员可以理解：在不脱离本发明的原理和宗旨的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由权利要求及其等同物限定。
提供前述内容主要是为了解释的目的。本领域的技术人员可以容易地认识到：递送载体或药物组合物中的各种组分的分子结构以及比例、本文所述的本发明的制造方法和其他参数可以以各种方式进一步加以改变或替换，而不偏离本发明的精神和范围。例如，对于上面示出的本发明的化合物的适应症的任何一种，由于被治疗的哺乳动物的反应有差异，所以可以应用不同于本文上面所述的特定剂量的有效剂量。同样地，所观察的特定的药理学反应可以根据并依赖于下列因素变化：所选择的特定活性化合物或者是否存在药物载体，以及制剂的类型和所用的施加方式，并且结果中这样的预期的变化或差异可以根据本发明的目的和实践来预期。因此，应该理解，本发明限于所附权利要求的范围并且这样的权利要求解释为合理宽的范围。
Claims (5)
1.一种抗菌、抗氧化特性的S3F8肽，其特征在于氨基酸序列如SEQ ID NO：1所示。
2.权利要求1所述的抗菌、抗氧化特性的S3F8肽在制备抑制细菌增殖的药物中的用途。
3.权利要求1所述的抗菌、抗氧化特性的S3F8肽和白细胞提取物在制备抑制细菌增殖的药物中的用途；其中白细胞提取物是将来自牛的NK细胞裂解后的上清液冻干制备获得的。
4.如权利要求3所述的用途，其中所述的细菌是金黄色葡萄球菌ATCC25923、大肠杆菌ATCC35218和副溶血弧菌ATCC 33845。
5.权利要求1所述的抗菌、抗氧化特性的S3F8肽和白细胞提取物在制备化妆中的用途，其中白细胞提取物是将来自牛的NK细胞裂解后的上清液冻干制备获得的。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311017323.7A CN117024525B (zh) | 2023-08-14 | 2023-08-14 | 一种白细胞提取物的制备以及在化妆品和药品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311017323.7A CN117024525B (zh) | 2023-08-14 | 2023-08-14 | 一种白细胞提取物的制备以及在化妆品和药品中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117024525A true CN117024525A (zh) | 2023-11-10 |
| CN117024525B CN117024525B (zh) | 2024-01-09 |
Family
ID=88639690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311017323.7A Active CN117024525B (zh) | 2023-08-14 | 2023-08-14 | 一种白细胞提取物的制备以及在化妆品和药品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117024525B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040028712A1 (en) * | 2002-08-12 | 2004-02-12 | Shepherd Walter B | Composition containing leukocyte extract for the whitening or lightening of skin |
| CN108567719A (zh) * | 2017-09-26 | 2018-09-25 | 上海蕙禾生物科技事务所 | 一种白细胞提取物及其制备方法与应用 |
| CN115089698A (zh) * | 2022-06-16 | 2022-09-23 | 北京绎源生物科技有限公司 | 改善皮肤的活性肽与干细胞外泌体在药品或化妆品中的应用 |
| CN116492280A (zh) * | 2023-03-22 | 2023-07-28 | 广州准优生物科技有限公司 | 白细胞提取物的制备方法及其在化妆品中的应用 |
-
2023
- 2023-08-14 CN CN202311017323.7A patent/CN117024525B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040028712A1 (en) * | 2002-08-12 | 2004-02-12 | Shepherd Walter B | Composition containing leukocyte extract for the whitening or lightening of skin |
| CN108567719A (zh) * | 2017-09-26 | 2018-09-25 | 上海蕙禾生物科技事务所 | 一种白细胞提取物及其制备方法与应用 |
| CN115089698A (zh) * | 2022-06-16 | 2022-09-23 | 北京绎源生物科技有限公司 | 改善皮肤的活性肽与干细胞外泌体在药品或化妆品中的应用 |
| CN116492280A (zh) * | 2023-03-22 | 2023-07-28 | 广州准优生物科技有限公司 | 白细胞提取物的制备方法及其在化妆品中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| NIELSEN, H.B.等: "CCZ82966.1", 《GENBANK》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117024525B (zh) | 2024-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6419253B2 (ja) | 不活性化細菌細胞製剤 | |
| KR102253418B1 (ko) | 피부 유산균 유래 엑소좀을 유효성분으로 포함하는 조성물 및 이의 제조방법 | |
| CN114703108B (zh) | 一株发酵粘液乳杆菌及其在改善面部泛红和i型玫瑰痤疮中的应用 | |
| EP0629213B1 (en) | Use of an immunostimulatory agent | |
| KR20180086062A (ko) | 바다제비집 복합 추출물을 유효성분으로 함유하는 여드름 피부의 피부 상태 개선용 조성물 | |
| CN117024525B (zh) | 一种白细胞提取物的制备以及在化妆品和药品中的应用 | |
| MXPA00005288A (es) | Una composicion y metodo para el tratamiento de infeccion bacterial. | |
| Abozahra et al. | Effects of Pomegranate (Punica granatum) Peel Methanolic Extract Dietary Supplementation on Oreochromis Niloticus Performance, Blood Health, Intestine Morphometry and Immunity | |
| KR20100022309A (ko) | 엔테로코커스 패컬리스 에스엘-5 유래 박테리오신을 포함하는 여드름 예방 및 치료용 조성물 | |
| US11077170B2 (en) | Antimicrobial peptide from skate skin and uses thereof | |
| RO112580B1 (ro) | Metoda pentru profilaxia si/sau tratamentul bolii asociate cu un nivel nedorit al factorului de necrozare tumorala (tnf) | |
| CN114984063B (zh) | 皮肤外用剂组合物及功能性食品组合物 | |
| KR101508717B1 (ko) | 누에 유래 혈림프를 포함하는 화장료 조성물 | |
| CN111481565B (zh) | 戈氏副拟杆菌的脂多醣用于抑制发炎反应的医药组合物的用途 | |
| JP3649787B2 (ja) | 魚類の腸球菌感染症用予防剤およびその用途 | |
| CN114306362A (zh) | 抗菌和抗氧化活性增强型黄芩苷酯衍生物的应用 | |
| KR102100168B1 (ko) | 팔손이분홍치, 아이리쉬모스, 알쏭이모자반 및 청각 복합추출물을 유효성분으로 함유하는 화장료 조성물 | |
| JP2014058459A (ja) | コラーゲン産生促進懸濁液の製造方法 | |
| JP3272023B2 (ja) | 白血球減少治療剤 | |
| US20090186111A1 (en) | Novel Bacteria and Pharmaceutically Active Products Obtained Therefrom | |
| US20100048476A1 (en) | Novel use of bacteriocin derived from enterococcus faecalis sl-5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |